

Summary of status of development and availability of avian influenza A(H7N9) candidate vaccine viruses and potency testing reagents

14 November 2017

Candidate vaccine viruses*

Antigenic prototype	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Guangdong/17SF003/2016	Wild type virus			WHO CCs
	IDCDC-RG56N[#]	Reverse genetics	CDC, USA	CDC, USA
A/Hong Kong/125/2017	Wild type virus			CDC, USA
	IDCDC-RG56B	Reverse genetics	CDC, USA	CDC, USA
A/Shanghai/2/2013 Synthetic HA&NA	Wild type virus			CDC, USA
	IDCDC-RG32A	Reverse genetics	CDC, USA	CDC, USA NIBSC, UK CBER, USA
	IDCDC-RG32A.3	Reverse genetics	CDC, USA	CDC, USA
	NIBRG-267	Reverse genetics	NIBSC, UK	NIBSC, UK
	CBER-RG4A	Reverse genetics	CBER, USA	CBER, USA
A/Anhui/1/2013	Wild type virus			WHO CCs
	NIBRG-268	Reverse genetics	NIBSC, UK	NIBSC, UK
	NIIDRG-10.1	Reverse genetics	NIID, Japan	NIID, Japan
	IDCDC-RG33A	Reverse genetics	CDC, USA	CDC, USA
	SJ005	Reverse genetics	SJCRH, USA	SJCRH, USA

[#]New candidate vaccine virus shown in blue

*These viruses are candidate vaccine viruses which have passed relevant safety testing and two-way haemagglutination inhibition (HI) tests. They can be handled under BSL-2 enhanced containment¹.

¹ http://www.who.int/biologicals/areas/vaccines/influenza/biosafety_risk_assessment_10may2013.pdf

Candidate vaccine viruses in preparation

Antigenic prototype	Developing Institute	Available from
A/Hunan/02650/2016	CCDC, China	pending

Institutes contact details for candidate vaccine viruses orders/information:

CBER: CBERshippingrequests@fda.hhs.gov
CDC: dwentworth@cdc.gov (Subject: CVV request)
NIBSC: standards@nibsc.org or enquiries@nibsc.org
NIID: nobusawa@nih.go.jp
SJCRH: richard.webby@stjude.org
WHO CCs: http://www.who.int/influenza/gisrs_laboratory/collaborating_centres/list/en/

Reference antigens

Starting materials		Ref. Ag. Lot number	Unitage (µgHA/ml)	Available from
Antigenic prototype	Candidate vaccine virus			
A/Anhui/1/2013	NIBRG-268	14/250	37	NIBSC, UK
A/Shanghai/2/2013	IDCDC-RG32A	2014/100B	72	TGA, Australia
	PR8-IDCDC-RG32A	78	60	CBER, USA**

** All requests for reagents to CBER will be evaluated upon justification provided.
 Distribution may be restricted

Sheep antisera

Antigenic prototype	Order Lot number	Available from
A/Anhui/1/2013	13/180	NIBSC, UK
	13/166 [§]	
A/Shanghai/2/2013	H7-Ab-1320 [#]	CBER, USA**
	H7-Ab-1322 ^{##}	
	H7-Ab-1322a ^{##}	

[§] Anti NA serum for tests of neuraminidase identification

[#] Primed with bromelain-cleaved HA from A/Mallard/Netherlands/12/2000 (H7N3), boosted with bromelain-cleaved HA from egg grown A/Shanghai/02/2013 PR8-IDCDC-RG32A reassortant; an additional boost with influenza H7 (A/Shanghai/02/2013) virus-like particles prepared in Vero cells

^{##} Primed and boosted with bromelain-cleaved HA from egg grown A/Shanghai/02/2013 PR8-IDCDC-RG32A reassortant; an additional boost with influenza H7 (A/Shanghai/02/2013) virus-like particles prepared in Vero cells

** All requests for reagents to CBER will be evaluated upon justification provided.
 Distribution may be restricted

The above-listed potency testing reagents for A(H7N9) vaccines have been developed with support from WHO Collaborating Centres (CCs) and Essential Regulatory Laboratories (ERLs) of the Global Influenza Surveillance and Response System (GISRS) and calibrated by the ERLs that provide advice to WHO as part of the influenza vaccine virus selection and development process.

ERLs contact details for reagent orders and other information:

CBER: CBERshippingrequests@fda.hhs.gov
NIBSC: standards@nibsc.org or enquiries@nibsc.org
TGA: influenza.reagents@health.gov.au

For other candidate vaccine viruses and potency testing reagents, please go to http://www.who.int/influenza/vaccines/virus/candidates_reagents/home/

For general enquiries, please contact gisrs-whohq@who.int